Dr. Ayalon is Vice President of Translational Science at Xilis. She has over 20 years of experience in drug discovery and drug development, leading R&D projects and teams in the early development of Biologics in multiple therapeutic areas including Immunology, Oncology, Metabolic diseases, and GI/Liver diseases.
Prior to joining Xilis Dr. Ayalon was Vice President of R&D of Kamada where she led all early therapeutics programs overseeing non-clinical and CMC as well as life cycle management of Kamada’s FDA-approved products. Previously, Dr. Ayalon served as Head of R&D at 89bio, where she had a leading role in the company establishment as a spin-out of Teva Pharmaceutical and in substantial fundraising and managed all R&D functions: non-clinical, translational science, early clinical development, CMC, regulatory and project management. Prior to that, Dr. Ayalon had leading R&D roles in several small and mid-size biotech companies. Dr. Ayalon received her Ph.D. in cell biology and Immunology from Tel-Aviv University and completed her postdoctoral research in molecular cancer biology at the Weizmann Institute of Science.
